ppi-1011
Recombinant proteinexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 29, 2023 (NCT05969977)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Lysophospholipid acyltransferase LPCAT4Supplementation
LPCAT4 supplementation
Chemistry & pharmacology
Loading structure…
SMILES
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COCCCCCCCCCCCCCCCC)COC(=O)CCCC[C@@H]1CCSS1- Mol. weight
- 815.32 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068521 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05969977 | Phase 1 | May 29, 2023 | BioPharma Services, MED-LIFE DISCOVERIES LP |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioPharma Services | For profit | 1 | 0 | 1 | 2023 |
| MED-LIFE DISCOVERIES LP | For profit | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1